Scott Gottlieb seems like the pharmaceutical industry's idea of a dream FDACommissioner, with pharma ties and an ideological bent towardderegulation.

But he has also been the only member of the Trump administrationto follow through on the president's fiery rhetoric about rising drug prices. Pharma claims to like thefree market. But in the year ahead, Gottlieb is set to prove howthe free market can cut both ways for drugmakers.

Gottlieb is a physician who became the FDA's DeputyCommissioner for Medical and Scientific Affairs in 2005. Afterleaving the agency in 2007, he served on pharma boards, worked inventure capital and was a resident fellow at the AmericanEnterprise Institute, a conservative think tank.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.